1-(4-tolyl)-3,3-dimethyltriazene, also known as **4-tolyldiazene**, is a **diazo compound** that is important in research for a few reasons:
**1. Synthesis and Reactivity:**
* **Versatile Precursor:** It acts as a versatile precursor for various synthetic reactions, particularly in the generation of diazoalkanes and diazonium salts. These intermediates are crucial for various organic transformations.
* **Click Chemistry:** The triazene moiety can be involved in click chemistry reactions, which are highly efficient and selective reactions used in drug discovery, materials science, and bioconjugation.
**2. Biological Activity:**
* **Antimicrobial and Anticancer Activity:** Some studies suggest that 1-(4-tolyl)-3,3-dimethyltriazene derivatives exhibit antimicrobial and anticancer activities. This potential makes them interesting candidates for drug development research.
* **DNA Binding:** Its structure allows it to bind to DNA, which can have implications for its biological activity.
**3. Theoretical and Computational Studies:**
* **Theoretical Model:** The compound is a popular model system for theoretical and computational studies of diazo compounds, particularly in exploring their electronic structure and reactivity.
**4. Other Applications:**
* **Dye Synthesis:** It can be used in the synthesis of various dyes, including azo dyes.
* **Polymer Chemistry:** Its ability to undergo polymerization reactions makes it relevant in the development of new polymers.
**It's important to note that while 1-(4-tolyl)-3,3-dimethyltriazene is a promising compound for various research fields, it is crucial to consider its potential toxicity and hazards.** Safety precautions should always be taken when handling this compound and any related experiments.
In summary, 1-(4-tolyl)-3,3-dimethyltriazene is a versatile diazo compound with potential applications in organic synthesis, click chemistry, drug discovery, and materials science. Its importance in research stems from its unique properties, reactivity, and potential for further development in various fields.
ID Source | ID |
---|---|
PubMed CID | 81618 |
CHEMBL ID | 3230455 |
SCHEMBL ID | 7862256 |
SCHEMBL ID | 17709235 |
MeSH ID | M0103032 |
Synonym |
---|
1-p-tolyl-3,3-dimethyltriazene |
1-triazene,3-dimethyl-1-(4-methylphenyl)- |
3,3-dimethyl-1-p-tolyltriazene |
triazene,3-dimethyl-1-p-tolyl- |
nsc-48821 |
nsc48821 |
1-(4-methylphenyl)-3,3-dimethyltriazene |
triazene,3-dimethyl-1-(p-methylphenyl)- |
u 14439 |
1-p-methylfenyl-3,3-dimethyltriazen |
wln: 1n1&nunr d1 |
7203-89-6 |
IDI1_012232 |
SR-01000641728-1 |
3,3-dimethyl-1-p-tolyltriazene, 97% |
triazene, 3,3-dimethyl-1-p-tolyl- |
nsc 48821 |
triazene, 3,3-dimethyl-1-(p-methylphenyl)- |
3,3-dimethyl-1-(p-methylphenyl)triazene |
1-p-methylfenyl-3,3-dimethyltriazen [czech] |
ccris 1994 |
1-triazene, 3,3-dimethyl-1-(4-methylphenyl)- |
1-(4-methylphenyl)-3,3-dimethyltriazine |
ai3-50824 |
1-(4-tolyl)-3,3-dimethyltriazene |
MAYBRIDGE3_000845 |
HMS1433G09 |
3,3-dimethyl-1-(4-methylphenyl)triaz-1-ene |
n-methyl-n-[(4-methylphenyl)diazenyl]methanamine |
CCG-52494 |
CHEMBL3230455 |
SCHEMBL7862256 |
SCHEMBL17709235 |
3,3-dimethyl-1-p-tolyl-triazen |
(e)-3,3-dimethyl-1-p-tolyltriaz-1-ene |
2E2JG4C5BD |
DTXSID801032012 |
Excerpt | Reference | Relevance |
---|---|---|
" The close correspondence of the two QSAR leaves essentially no means for the synthesis of more potent, less toxic triazenes." | ( Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice. Greenberg, N; Hansch, C; Hatheway, GJ; Quinn, FR, 1978) | 0.26 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1123539 | Mutagenicity in Salmonella typhimurium strain TA92 assessed as number of bacterial revertants after 2 days by Ames test in presence of rat liver S9 fraction | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study. |
AID1148443 | Toxicity in CDF1 mouse assessed as concentration required for producing T/C of 140 | 1978 | Journal of medicinal chemistry, Jun, Volume: 21, Issue:6 | Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice. |
AID1148441 | Toxicity in rat assessed as concentration required for producing T/C of 140 | 1978 | Journal of medicinal chemistry, Jun, Volume: 21, Issue:6 | Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice. |
AID1132822 | Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase of host lifespan | 1978 | Journal of medicinal chemistry, Jun, Volume: 21, Issue:6 | Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (62.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |